BEATHealthcare · Health Information ServicesThe 3 Wall Street analysts covering HeartBeam, Inc. hold a median 12-month price target of $3.5 — +723.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 12 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores HeartBeam, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (87): Smaller than most of the companies we track.
Quality (2): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BEAT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +723.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Sept 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 14 July 2026 | Maxim Group | Initiates | Buy | $2.00 |
| 14 July 2026 | Maxim Group | Initiates | Buy | — |
| 22 May 2026 | HC Wainwright & Co. | Maintains | Buy | $5.50 → $2.50 |
| 22 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 May 2026 | Benchmark | Maintains | Speculative Buy | — |
| 15 May 2026 | Benchmark | Maintains | Speculative Buy | $8.00 → $5.00 |
| 31 Mar 2026 | B. Riley Securities | Initiates | Buy | — |
| 30 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 27 Mar 2026 | D. Boral Capital | Initiates | Buy | — |
| 16 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Dec 2025 | Benchmark | Upgrade | Buy | — |
| 10 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Dec 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 15 Nov 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 4 Sept 2024 | Benchmark | Reiterates | Speculative Buy | $8.00 |
| 13 May 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 25 Mar 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 16 Nov 2023 | Benchmark | Reiterates | Speculative Buy | — |
| 24 Aug 2023 | Benchmark | Reiterates | Speculative Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BEAT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 12 Oct 2026, HeartBeam, Inc. returned −74.2% against +20.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 81% of US stocks
Cheaper than 29% of US stocks
Cheaper than 68% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 5% of US stocks
Higher than 1% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
HeartBeam, Inc. has a market value of $27.0M and an enterprise value of $21.9M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$20.3M.
Free cash flow in the twelve months to 30 June 2026: −$14.0M.
Trailing P/E: −0.8×; forward P/E: −0.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
HeartBeam, Inc. employs 16 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own HeartBeam, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
HeartBeam, Inc. announced it received Breakthrough Device Designation from the U.S. Food and Drug Administration for its at-home cardiac assessment tool. The designation applies to the company's at-home heart attack detection system.
Why it matters — FDA Breakthrough Device Designation could help expedite the development and review of HeartBeam's at-home cardiac assessment product.
HeartBeam, Inc. announced it received FDA Breakthrough Device Designation for its heart attack assessment technology. This designation is intended to expedite the development and review of the device.
Why it matters — For HeartBeam watchers, this designation reflects regulatory recognition that may support the company's product development and commercial pathway for its heart attack assessment device.
HeartBeam, Inc. issued a letter to shareholders, as announced via Business Wire from Santa Clara, California. The announcement details no specific events beyond the release of the shareholder letter itself.
Why it matters — A letter to shareholders may offer BEAT watchers insight into the company's recent performance, strategy, or outlook directly from management.
HeartBeam, Inc. (BEAT) published the transcript of its Q2 2026 earnings call on Seeking Alpha. The transcript covers the company's quarterly earnings discussion.
Why it matters — BEAT watchers would turn to the transcript for management's commentary on the company's second-quarter results and outlook.
HeartBeam, Inc. announced its financial results for the second quarter of 2026 via a Business Wire release dated from Santa Clara, California.
Why it matters — Earnings reports provide insight into the company's recent financial performance, which is key information for those following HeartBeam.
The 3 Wall Street analysts covering HeartBeam, Inc. have a median 12-month price target of $3.5, with estimates ranging from $2 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering HeartBeam, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks HeartBeam, Inc. 19 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Oct 2026, HeartBeam, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (87 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +723.5% from the last close, and Ticker Nerd's factor model ranks HeartBeam, Inc. 19 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering HeartBeam, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BEAT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $5 over the next 12 months.
HeartBeam, Inc. returned -74.2% over the 12 months to 12 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
HeartBeam, Inc. is a medical technology company that develops cardiac diagnostic solutions for use both inside and outside clinical settings.
The most recent item we track (Benzinga, 5 Oct 2026): "HeartBeam Secures FDA Designation for At-Home Heart Attack Detection System". HeartBeam, Inc. announced it received Breakthrough Device Designation from the U.S. Food and Drug Administration for its at-home cardiac assessment tool. The designation applies to the company's at-home heart attack detection system.
HeartBeam, Inc. is a medical technology company that develops cardiac diagnostic solutions for use both inside and outside clinical settings. The company’s core offering is a portable, cable-free ECG platform designed to capture the heart’s electrical activity from three dimensions and synthesize it into a 12-lead ECG for physician review. Its products and software are aimed at helping clinicians detect and monitor arrhythmias and other cardiac conditions through remote and ambulatory workflows. HeartBeam’s current product portfolio includes a patient-held ECG device, a companion mobile application, physician software, and cloud-based analysis tools that support cardiac assessment and care coordination. Based in Santa Clara, California, HeartBeam operates in the healthcare technology market, with a focus on ambulatory cardiovascular diagnostics and telehealth-enabled cardiac monitoring.
CEO Mr. Robert P. Eno · 16 employees · United States · https://www.heartbeam.com
